Renew has developed a novel enzymatic platform by synthetic biology to create a diverse pipeline of proprietary therapeutic molecules (i.e. alkylresorcinol scaffold derivatives; similar to CBGA). Uniquely, Renew’s scaffold molecules pass the blood brain barrier and engage a classic cellular receptor that controls inflammation (i.e. PPAPγ), together making this family of molecules particularly useful for indications of neuro...
Renew has developed a novel enzymatic platform by synthetic biology to create a diverse pipeline of proprietary therapeutic molecules (i.e. alkylresorcinol scaffold derivatives; similar to CBGA). Uniquely, Renew’s scaffold molecules pass the blood brain barrier and engage a classic cellular receptor that controls inflammation (i.e. PPAPγ), together making this family of molecules particularly useful for indications of neuro-therapeutics. Renew is specifically focused on developing therapeutics to treat neuroinflammation pathologies, with specific focus on Traumatic Brain Injury (TBI).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.